EP1438976A4 - Hydrogel biocompatible polyfonctionnel et procede de production associe - Google Patents

Hydrogel biocompatible polyfonctionnel et procede de production associe

Info

Publication number
EP1438976A4
EP1438976A4 EP01274505A EP01274505A EP1438976A4 EP 1438976 A4 EP1438976 A4 EP 1438976A4 EP 01274505 A EP01274505 A EP 01274505A EP 01274505 A EP01274505 A EP 01274505A EP 1438976 A4 EP1438976 A4 EP 1438976A4
Authority
EP
European Patent Office
Prior art keywords
acrylamide
hydrogel
water
bis
ethylene bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01274505A
Other languages
German (de)
English (en)
Russian (ru)
Other versions
EP1438976A1 (fr
EP1438976B1 (fr
Inventor
Vladislav Victorovich Lopatin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioform International SA
Original Assignee
Biopharma Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharma Development Ltd filed Critical Biopharma Development Ltd
Publication of EP1438976A1 publication Critical patent/EP1438976A1/fr
Publication of EP1438976A4 publication Critical patent/EP1438976A4/fr
Application granted granted Critical
Publication of EP1438976B1 publication Critical patent/EP1438976B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/16Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0025Crosslinking or vulcanising agents; including accelerators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/02Elements
    • C08K3/08Metals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S524/00Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S524/916Hydrogel compositions

Definitions

  • the organism is mammals.
  • ne ⁇ b ⁇ dimymi 25 ne ⁇ b ⁇ dimymi ⁇ izi ⁇ - ⁇ imiches ⁇ imi ( ⁇ edelennaya ⁇ l ⁇ n ⁇ s ⁇ and ⁇ imiches ⁇ aya ine ⁇ n ⁇ s ⁇ , s ⁇ s ⁇ bn ⁇ s ⁇ ⁇ usad ⁇ e or nabu ⁇ aniyu ⁇ sle ⁇ mescheniya in ⁇ ganizm) and bi ⁇ l ⁇ giches ⁇ imi (bi ⁇ l ⁇ giches ⁇ aya ine ⁇ n ⁇ s ⁇ in chas ⁇ n ⁇ s ⁇ i, ⁇ su ⁇ s ⁇ vie ⁇ ea ⁇ tsii ⁇ zhoniya or in ⁇ y ⁇ anev ⁇ y ⁇ ea ⁇ tsii) sv ⁇ ys ⁇ vami. Otherwise, the material must have a format suitable for introducing it into the muscle tissue with minimal trauma for the patient’s organism.
  • hydrogels on the main polylamide may be used. Izves ⁇ en gid ⁇ gel on ⁇ sn ⁇ ve s ⁇ lime ⁇ a a ⁇ ilamida me ⁇ ilen- with bis-a ⁇ ilamid ⁇ m in ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a, ⁇ isanny in ⁇ a ⁇ en ⁇ e ⁇ ⁇ e 2114578, for ⁇ ednaznachenny izg ⁇ vleniya ⁇ us ⁇ ali ⁇ a eyes s ⁇ de ⁇ zhaschy a 1: 1 0 wt.% And s ⁇ lime ⁇ a a ⁇ ilamida me ⁇ ilen 5-bis a ⁇ ilamida, in vzya ⁇ y ⁇ by weight of 100: 2.26, and 89 by weight of% of physiological production.
  • P ⁇ i e ⁇ m ⁇ tsess s ⁇ lime ⁇ izatsii ⁇ v ⁇ dya ⁇ in ⁇ dnu s ⁇ adiyu, z ⁇ in ⁇ aches ⁇ ve ⁇ e ⁇ sidny ⁇ initsia ⁇ v ⁇ lime ⁇ izatsii is ⁇ lzuyu ⁇ mixture ⁇ e ⁇ sul ⁇ a ⁇ a amm ⁇ niya and ⁇ e ⁇ ame ⁇ ile ⁇ ilendiamina, and ⁇ aches ⁇ ve v ⁇ dn ⁇ y s ⁇ edy be ⁇ u ⁇ a ⁇ i ⁇ gennuyu v ⁇ du or ⁇ as ⁇ v ⁇ ⁇ l ⁇ ida na ⁇ iya.
  • the hydrogel obtained by this method has an insufficient degree of crosslinking, which is due to the low temperature mode of operation
  • the process of sompolimerization and its one-stage E ⁇ ⁇ iv ⁇ di ⁇ ⁇ bys ⁇ mu ⁇ as ⁇ aniyu s ⁇ edini ⁇ eln ⁇ y ⁇ ani in im ⁇ lan ⁇ i ⁇ vannny gel and ⁇ eg ⁇ bys ⁇ y usad ⁇ e and ⁇ ez ⁇ btsii ( ⁇ . ⁇ . ⁇ ek ⁇ eg e ⁇ .
  • the hydrogel produced by this method contains unrelated molecules of methylethylenediamine, free ⁇ 2 radicals and a small amount of 1, it means 1 E ⁇ m ⁇ zhe ⁇ vyzyva ⁇ a ⁇ ivnuyu ase ⁇ iches ⁇ uyu v ⁇ s ⁇ ali ⁇ elnuyu ⁇ ea ⁇ tsiyu on ⁇ anney s ⁇ adii introduction gid ⁇ gelya in ⁇ ganizm (see. ⁇ . ⁇ ek ⁇ eg e ⁇ a ⁇ " ⁇ es ⁇ aYe ⁇ u ⁇ g ⁇ Shs ⁇ uasgu ⁇ at ⁇ e de ⁇ ⁇ gtasgu ⁇ a ⁇ zzie gez ⁇ ze!
  • a hydrogel gel described in the patent 21 ° 2127129, containing 1, 0 to 8.0 wt.%, Is obtained, which contains a total of 99% of the total weight of 92% of the product. .
  • the method of obtaining this material is also described in
  • a further one task is to reduce the tissue response of the body to the implant by reducing the content of free radicals and cartridges in the hydraulic gel.
  • 15 P ⁇ s ⁇ avlennye problem ⁇ esheny ⁇ em, ch ⁇ ⁇ edl ⁇ zhen ⁇ li ⁇ un ⁇ tsi ⁇ nalny bi ⁇ s ⁇ vmes ⁇ imy gid ⁇ gel, s ⁇ de ⁇ zhaschy ⁇ e ⁇ echn ⁇ -sshi ⁇ y s ⁇ lime ⁇ a ⁇ ilamida s ⁇ crosslinking agen ⁇ m and v ⁇ du, ⁇ y, s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniya in ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a s ⁇ de ⁇ zhi ⁇ mixture ⁇ , ⁇ '- me ⁇ ilen bis a ⁇ ilamida, ⁇ , ⁇ ' - ethylene-bis-acrylamide and 20% of the angle for the following ratio of weight percentages:
  • the indicated biocompatible hydrogel contains bi-distilled and odorogenic water.
  • the compatible hydrogel has a pH of 3.5-7.5.
  • the indicated crosslinked compound is from 2.0 to 5 to 15.0 wt.% Of the total weight of the hydrogel.
  • the indicated biocompatible hydrogel contains the following ratio of components in wt.%:
  • the indicated biocompatible hydrogel may also contain the following ratio of components in wt.%: 15 Ukrilamida - 1, 3 - 15,
  • the method may also be implemented when in stock.
  • a crosslinking agent takes a mixture of ⁇ , ⁇ '- methylene bis acrylamide, ⁇ , ⁇ '- ethylene bis acrylamide, polyvinyl, vinylpyrrolidene and / or ethylene bis
  • the gel is washed in hot water, which has a temperature of 70-110 ° C, for at least 3 hours, at a weight of 8-10: ⁇
  • Green As a part of the initiative for the elimination of the charge, you must not consume water and / or 20 ammonia in quantities not exceeding 0.33 wt.% Of the total weight of the original.
  • bidistilled and hazardous water is available.
  • ⁇ a ⁇ izves ⁇ n ⁇ ma ⁇ e ⁇ ial as gid ⁇ gelya on ⁇ sn ⁇ ve s ⁇ lime ⁇ a 25 a ⁇ ilamida and sshivayuschi ⁇ agen ⁇ v ⁇ eds ⁇ avlyae ⁇ s ⁇ b ⁇ y ⁇ e ⁇ me ⁇ nuyu se ⁇ ⁇ e ⁇ echn ⁇ -sshi ⁇ g ⁇ s ⁇ lime ⁇ a a ⁇ ilamida s ⁇ crosslinking agen ⁇ ami in yachey ⁇ a ⁇ ⁇ y ude ⁇ zhivae ⁇ sya v ⁇ dnaya s ⁇ eda in ⁇ y s ⁇ de ⁇ zhi ⁇ sya ne ⁇ e neus ⁇ an ⁇ vlenn ⁇ e ⁇ liches ⁇ v ⁇ nesvyazann ⁇ g ⁇ initsia ⁇ a ⁇ lime ⁇ izatsii, ⁇ a ⁇ ⁇ a ⁇ ne ⁇ e, ⁇ a ⁇ zhe neu
  • FIG. 16 - Hydro-gel absorbing method is a product available in the Russian Federation for Patent 21 ° 2127129 under the name “story ⁇ endeavour ⁇ ⁇ » »» ”; For example, they are made in the region of 4000-500 cm “1.
  • the product extract is provided with a 5 hydrogel
  • a photograph of a histologically-logged biopsy of a tissue of a cassia taken after 30 days of a free delivery is provided, which is available for use (200); 20 ig. 36 - phytogroup of a histological and biological biopsy of the shell, taken after 30 days after a direct injection of the hydrophobic gel “bypass”; in Fig. 4a, a photograph of a histologically harmless biopsy of a dog, taken after 9 months after a prompt injection of a hydro-pump, is provided;
  • Fig. 4b phytogroup of histological and biological damage of a dog, taken after 9 months after a direct injection of the hydrophobic gel “bypass”; on ⁇ ig.5a ⁇ eds ⁇ avlena ⁇ g ⁇ a ⁇ iya gis ⁇ l ⁇ giches ⁇ g ⁇ s ⁇ eza bi ⁇ sii z ⁇ ⁇ ani chel ⁇ ve ⁇ a, vzya ⁇ y che ⁇ ez 12 months ⁇ sle subglandulya ⁇ n ⁇ y im ⁇ lan ⁇ atsii ⁇ edlagaem ⁇ g ⁇ gid ⁇ gelya for mamma ⁇ las ⁇ i ⁇ i ( ⁇ as ⁇ a gema ⁇ silin-e ⁇ zin ⁇ m, x 400), where ⁇ - s ⁇ edini ⁇ eln ⁇ annaya ⁇ a ⁇ sula,
  • ⁇ - transcendental zone C is a fragment of a hydrogel
  • is a macrophage on the part of the capsule, a part of the implant
  • the product is: - ⁇ rilamide (asgu ⁇ at ⁇ e): ⁇ 3 ⁇ ⁇ ⁇ , mol. weight 71.08, white crystalline product without a deposit; melting point 84.5 ° C; w ⁇ izv ⁇ ds ⁇ v ⁇ ⁇ i ⁇ my ⁇ dta ( ⁇ a ⁇ al ⁇ g " ⁇ ea ⁇ ivy for bi ⁇ imii and issled ⁇ vany in ⁇ blas ⁇ i es ⁇ es ⁇ venny ⁇ nau ⁇ » ⁇ , 1999, p 47, ⁇ a ⁇ al ⁇ zhny ⁇ ° ⁇ 8887.);
  • the process is as follows: 15 For the preparation of a reactive mixture, bidistilled and antigenic water having a pH of 5.6 is taken.
  • acrylamide and cross-linking agents for example, mixtures of ⁇ , ⁇ '-methylene-bis-acrylamide, ⁇ , ⁇ -ethylene-bis-acrylamide and a slight increase in the amount of 65 5: 0.2 - 6.5: 0.2 - 34.0: 0.1 - 3.0), or a mixture of ⁇ , ⁇ '-methylene bis acrylamide, ⁇ , ⁇ '-ethylene bis acrylamide , price, vinyl pyridolide or ethylene bis- (hydroxyethylenitrile) -acetate acid, or the sum of the last (taken in the given mass ratio at: 0.2 - 6.0: 6.0 - 6.0: - 6.0 - 6.0 0: 0.1 - 3.0: 0.1-2.5), and for this 25, the total mass of the original components in the industry is 2.0-15.0%. (Aromatic quantities in the mixture produce a hydrogel of different density and elasticity).
  • the ready-to-use mixture is filtered through bactericidal suitable filters, for example, brand ⁇ 8273 with a size of 5 0.45 ⁇ , which is a unit of 90 °. After this incubation
  • the level of dosing is not higher than 1, 0 (mg of dosing per 1 liter).
  • the migration of the drug was no more than 0.12 mg / l and at a permissible level of 200 mg / l in drinking water;
  • hydrogel For the production of hydrogel, 384 ml of bidistilled apirogenic water with a pH of 5.6 were taken and 13 g of acrylamide, 0.5 g of ⁇ , ⁇ '-methylene bis-acylamide, 2,3- ⁇ - ⁇ , and 0.2 g of rivals, ideal for biological purposes. Then in the original
  • the resulting hydrogel was sterilized by autoclaving (at a temperature of 120 ° ⁇ and a pressure of 1, 2 atm.) For 20 minutes.
  • Index of application for the methodology described in the "Medicine for Physical Chemistry", ⁇ ., 1974, pp.
  • the resulting sample of the hydrogel had the following physical and chemical 15 characteristics:
  • the present look is a colorless, polished, intense gel
  • the level of dispersion is 0.1 (mg of bromine per 1 liter).
  • tissue blocks 20 were fixed at 96 ° ethyl alcohol or neutral raspberry and poured into a paraffin.
  • the capsule ⁇ (Fig. For) remains in the market. It is a large part of the connective tissue, the quantity of fibroids decreases in size, and in the remaining cells, the content of ⁇ ( ⁇ ) decreases. ⁇ The reserved area ⁇ Fragments from the gel remain, which are disposed of by the macrophages. The internal capsule rotation was partially sent out by the macros. ⁇ satin worship The following sections (60 and 90 days) of the capsule structure are not
  • junction capsule around the implant is thicker than implantation of the claimed material.
  • the internal capsule has a large number of malfunctioning and there is no significant loss of memory
  • hydrogel - ontropypa (osteochemistry of hematoxylsine-eosin, ⁇ 400).
  • this photo gel As can be seen from this photo gel, it is equipped with connecting rods, connecting fibers, markers, leukocytes, and separate neutral leukemia. Partial lysis of the gel and its resorption is noted.
  • the “old” fibrous capsule is almost always reversed.
  • the implant is equipped with a closed connective-cassule ⁇ without an internal fibroblastic word, which has a place in the cavity of the silicone.
  • connecting-cable rods categories, markers, and short-circuit immunity waves
  • Part of the methods has a large penile cytoplasm (active phagosis).
  • the connecting tissue knit separates the gel near the capsule into fragments.
  • hydrogel For the production of hydrogel, 870 ml of bidistilled apirogenic water, having ⁇ , 5, 6, was dissolved in it; 81; acrylamide, 1 1, 5 g, bis-acrylamide, 4.6 grams of alcohol. Then, in the initial solution, 8 ml of 15 mg of water were added to initiate the polymerization. The resulting mixture was filtered, as described in step 1, and placed on an incubation of 80 ° C for 2 hours, then we washed the gel at a standstill of 80 5 hours at a temperature of 125 ° C. 20 The resulting hydraulic gel was sterilized, as described in Example 1.
  • Hydrogel had the following physical and chemical characteristics, which were divided in accordance with the methods indicated in Example 1:
  • the present view is a palpable mild yellow gel; 25 Indication of investments - 1, 336; ⁇ - 4.0;
  • the content of monomers of acrylamide and bisacrylamide is up to 0.4 ⁇ civil;
  • the level of dispersion is 0.9 (mg of bromine per 1 liter); Bacteriostatic properties
  • hydrogel gel was used for the plasticization of the external muscle. Hydrogel gel in a volume of 50 ml. was injected into the external muscle of a patient I., 42 years old, to eliminate the defect after an irradiated injury. The patient was observed in the aftercare period of 6 months. There were no distant phenomena and no currents. Gel was not available. The simplicity was achieved.
  • Example 3. 5 For the production of the hydrogel, 972 ml of bidistilled apirogenic water with a pH of 5.6 was taken, 22.5 g acrylamide, 0.375 g ⁇ , ⁇ '-methylene bis--b réelle ⁇ - acrylamide, 0.06 g of poison and 0.065 g of ethylene bis (hydroxyethylenitrile) - tetracycide acid. Then, 2.5 g of ammonia sulfate was introduced into the original solution.
  • Hydrogel had the following physical and chemical characteristics, which were divided in accordance with the methods indicated in Example 1:
  • the present look is a colorless gel; 20 Indication of investments - 1, 334; ⁇ - 6.8;
  • the content of the acromilamides is absent;
  • the level of dispersion is 0.15 (mg of bromine per 1 liter).
  • the pressure zone of bacteria growth is 1, 5 mm.
  • hydrogel samples were implanted in a convenient dog and removed after 3 and 6 months.
  • the proposed hydrogel which contains, as a crosslinking agent, a mixture of ⁇ , ⁇ '-methylene-bis-acrylamide, ⁇ , ⁇ -ethylene bis-5 acrylamide and 4 months of age, is 6 months old. 15% of water is consumed;
  • the proposed hydrogel containing a cross-linking agent as a mixture of ⁇ , ⁇ '-methylene bis-acrylamide, ⁇ , ⁇ -ethylene bis acrylamide, ileus, and is non-toxic. 5% of water is consumed by implants, and after 6 months, 9% of water is consumed after implantation.
  • a dry gel with a low dry content of up to 3% is easy to inject through the thinned needles and can be used to lay soft tissues.
  • a dry gel with a low dry content of up to 3% is easy to inject through the thinned needles and can be used to lay soft tissues.
  • the resulting hydrogel was used to maintain a handy patch and remove facial wrinkles. Hydrogel gel in a volume of 1 ml. a total of 47 years was introduced. The patient was observed in the after-treatment period for 12 months with periodic treatment times in one month. Distinctive and allergic phenomena have not been established. c. The desired cosmetic effect has been achieved.
  • the resulting hydraulic gel was sterilized by autoclaving, as described in Example 1.
  • the material had the following physical and chemical characteristics: its present appearance is a colorless, highly opaque, polucheznaya gel;
  • composition of monomers 0.04 ⁇ transaction; 15
  • the level of breakdown is 0.05 (mg of bromine per 1 liter).
  • Bacteriological properties the pressure zone of bacteria growth is 2.0 mm.
  • the resulting hydrogel was used to remove overspray. Hydrogel in the amount of 2 g was introduced by the patient, 27 years. Patient 20 was observed in the after-treatment period for 12 months with periodic treatment times in one month. There were no distant phenomena and no currents. The desired cosmetic effect has been achieved.
  • hydrogel For the production of the hydrogel, 375 ml of bidistilled organic water was taken at a pH of 5.6, and 23.75 g of acrylamide, 1, 075 g ⁇ , ⁇ '-methylene-bis-aqylamide, 0.1, 0,1-methylamide, 0.1 were dissolved in it. , 0.03g. Then, 0.02 g of ammonium sulfide and 1 ml of 30% hydrogen peroxide were introduced into the initial solution. The resulting mixture was filtered, as described in Example 1, and placed on incubation Temp. 50 ° C for 16 hours, then wash the gel in 3.5 l of hot water and temperature 100 ° C for 4.0 hours and incubate another 1 hour at 130 ° C.
  • the resulting hydraulic gel was sterilized by autoclaving, as described in Example 1.
  • the material had the following physical and chemical characteristics: Appearance - colorless gel; The indicator of investments - 1, 348; ⁇ - 4.8; Density - 1, 0g / cm 3 ;
  • the proposed hydrogel practically does not cause tissue reaction, does not cause sensitization of the organism, does not cause Disruptive and non-critical changes and may be used for endoprosthesis and commercial soft tissue repair, as well as for endorsement of the parts and accessories Compared with a known hydrogel -
  • the proposed hydrogel has a lower low-tissue response of the organism to its implantation, a higher rate of implantation, and a lower degree of amenity.
  • P ⁇ edlagaemy gid ⁇ gel m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ a ⁇ zhe in ⁇ aches ⁇ ve na ⁇ lni ⁇ elya ⁇ i izg ⁇ vlenii end ⁇ ez ⁇ v, s ⁇ de ⁇ zhaschi ⁇ ⁇ b ⁇ l ⁇ ch ⁇ u and na ⁇ lni ⁇ el and ⁇ a ⁇ zhe in ⁇ aches ⁇ ve de ⁇ for le ⁇ a ⁇ s ⁇ venny ⁇ ⁇ e ⁇ a ⁇ a ⁇ v ⁇ i dli ⁇ eln ⁇ m medi ⁇ amen ⁇ zn ⁇ m treatment na ⁇ ime ⁇ , ⁇ u ⁇ ley or abstsess ⁇ v and ⁇ aches ⁇ ve n ⁇ si ⁇ elya for ⁇ ul ⁇ ivi ⁇ vaniya ⁇ le ⁇ chel ⁇ ve ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Colloid Chemistry (AREA)
EP01274505A 2001-09-28 2001-09-28 Hydrogel biocompatible polyfonctionnel et procede de production associe Expired - Lifetime EP1438976B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2001/000392 WO2003026711A1 (fr) 2001-09-28 2001-09-28 Hydrogel biocompatible polyfonctionnel et procede de production associe

Publications (3)

Publication Number Publication Date
EP1438976A1 EP1438976A1 (fr) 2004-07-21
EP1438976A4 true EP1438976A4 (fr) 2007-04-18
EP1438976B1 EP1438976B1 (fr) 2007-12-19

Family

ID=20129652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01274505A Expired - Lifetime EP1438976B1 (fr) 2001-09-28 2001-09-28 Hydrogel biocompatible polyfonctionnel et procede de production associe

Country Status (12)

Country Link
US (1) US7294348B2 (fr)
EP (1) EP1438976B1 (fr)
CN (1) CN1257752C (fr)
AT (1) ATE381356T1 (fr)
BR (1) BR0117137B1 (fr)
CA (1) CA2461821C (fr)
DE (1) DE60132025T2 (fr)
DK (1) DK1438976T3 (fr)
ES (1) ES2298195T3 (fr)
MX (1) MXPA04002967A (fr)
RU (1) RU2205034C1 (fr)
WO (1) WO2003026711A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303798D0 (en) * 2003-02-19 2003-03-26 Bioartem Ltd Gel
GB0327310D0 (en) * 2003-11-24 2003-12-24 Oztech Pty Ltd Pressure impulse mitigation
DE102007040370B4 (de) * 2007-08-20 2011-06-16 Eberhard-Karls-Universität Tübingen Universitätsklinikum Kollagenhaltiger Zellträger
DE102009005534B3 (de) * 2008-12-18 2010-04-01 Heraeus Medical Gmbh Sporozide Zusammensetzungen und deren Verwendung
US11090387B2 (en) 2008-12-22 2021-08-17 The Trustees Of The University Of Pennsylvania Hydrolytically degradable polysaccharide hydrogels
US9486404B2 (en) * 2011-03-28 2016-11-08 The Trustees Of The University Of Pennsylvania Infarction treatment compositions and methods
RU2499003C1 (ru) * 2012-03-22 2013-11-20 Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) Способ получения полиакриламидного гидрогеля
RU2493173C1 (ru) * 2012-03-22 2013-09-20 Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) Способ получения полиакриламидного гидрогеля
AU2013300171B2 (en) * 2012-08-09 2017-09-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for preparing biological specimens for microscopic analysis
RU2545806C1 (ru) 2013-12-26 2015-04-10 Международная коммерческая компания "НЬЮКРОСС ВЕНТУРЕС ЛТД" Материал медицинского назначения "матрексин" на основе полиакриламидного гидрогеля и способ его получения (варианты)
EP3125218A4 (fr) * 2014-03-24 2017-04-12 Fujifilm Corporation Composition de gel aqueux pour fantôme d'organe et fantôme d'organe
AU2015266894A1 (en) 2014-05-30 2016-08-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging large intact tissue samples
WO2017096248A1 (fr) * 2015-12-02 2017-06-08 Clearlight Diagnostics Llc Procédés de préparation et d'analyse d'échantillons de tissu tumoral pour la détection et la surveillance de cancers
US11254974B2 (en) 2016-02-10 2022-02-22 The Board Of Trustees Of The Leland Stanford Junior University RNA fixation and detection in clarity-based hydrogel tissue
RU2633490C1 (ru) * 2016-11-23 2017-10-12 Общество с ограниченной ответственностью "Медицина 3Д" Материал для замещения дефектов мягких тканей
PL241064B1 (pl) 2018-10-01 2022-08-01 Dolniak Blazej Sposób wytwarzania lepko-sprężystego żelu uzupełniającego maź stawową i lepko-sprężysty żel uzupełniający maź stawową
WO2023239695A1 (fr) * 2022-06-06 2023-12-14 Phrixionls, Llc Prophylaxie et traitement de cartilage dégradé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2088234C1 (ru) * 1994-11-25 1997-08-27 Институт высокомолекулярных соединений РАН Водорастворимая бактерицидная композиция и способ ее получения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050012A1 (de) 1979-11-06 1982-05-06 I Bilko Polyacrylamide gel for medical and biological application and method of its preparation
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US5941909A (en) * 1995-02-14 1999-08-24 Mentor Corporation Filling material for soft tissue implant prostheses and implants made therewith
US5658329A (en) * 1995-02-14 1997-08-19 Mentor Corporation Filling material for soft tissue implant prostheses and implants made therewith
RU2127095C1 (ru) * 1996-05-28 1999-03-10 Владислав Викторович Лопатин Эндопротез молочной железы
RU2127129C1 (ru) * 1996-05-28 1999-03-10 Владислав Викторович Лопатин Способ получения гелеобразного материала для пластики мягких тканей
RU2146127C1 (ru) * 1996-08-07 2000-03-10 Закрытое акционерное общество "Агрофарм-Питер-Сиб" Мазь для лечения инфицированных ран
BG102375A (en) * 1997-08-26 1999-11-30 Пегас Оод Inoculation biocompatible hydrophilic gel, method for its preparation and application
AU2001900A (en) * 1999-12-29 2001-07-16 Progen S.R.L. Biocompatible hydrogel and method of its production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2088234C1 (ru) * 1994-11-25 1997-08-27 Институт высокомолекулярных соединений РАН Водорастворимая бактерицидная композиция и способ ее получения

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199826, Derwent World Patents Index; AN 1998-295476, XP002423139 *

Also Published As

Publication number Publication date
RU2205034C1 (ru) 2003-05-27
DK1438976T3 (da) 2008-04-28
WO2003026711A1 (fr) 2003-04-03
BR0117137B1 (pt) 2014-01-28
MXPA04002967A (es) 2004-07-15
CA2461821C (fr) 2011-03-15
EP1438976A1 (fr) 2004-07-21
DE60132025T2 (de) 2008-12-04
US7294348B2 (en) 2007-11-13
US20040241241A1 (en) 2004-12-02
ATE381356T1 (de) 2008-01-15
DE60132025D1 (de) 2008-01-31
BR0117137A (pt) 2004-10-13
CA2461821A1 (fr) 2004-04-03
CN1257752C (zh) 2006-05-31
ES2298195T3 (es) 2008-05-16
EP1438976B1 (fr) 2007-12-19
CN1549732A (zh) 2004-11-24

Similar Documents

Publication Publication Date Title
WO2003026711A1 (fr) Hydrogel biocompatible polyfonctionnel et procede de production associe
US4409332A (en) Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US5633001A (en) Composition and a method for tissue augmentation
US5658593A (en) Injectable compositions containing collagen microcapsules
CA1295259C (fr) Procede permettant d'augmenter les tissus mous avec de la pyrrolidone polyvinylique reticulee
DE2706135A1 (de) Verdickungsmittel fuer ausgeschiedenen darminhalt und harn
WO2006102676A1 (fr) Elements de remplissage dermal d’oxyde de polyethylene et dispositifs associes
AU2001281763B2 (en) Polyacrylamide hydrogel and its use as an endoprosthesis
KR101776675B1 (ko) 콜라겐 하이드로겔 제조용 멀티 시린지
WO2003084573A1 (fr) Hydrogel biocompatible multifonctions et procede de fabrication correspondant
Firsov et al. Biodegradable implants containing gentamicin: drug release and pharmacokinetics
CA2935110A1 (fr) Materiau a vocation medicale a base d'hydrogel de polyacrylamide et procede de fabrication
CN101455628B (zh) 一种眼用凝胶组合物的制备方法
RU2127129C1 (ru) Способ получения гелеобразного материала для пластики мягких тканей
WO2001049336A1 (fr) Hydrogel biocompatible et procede de production
Gulchexra et al. USING THE STATE-OF THE ART TECHNIQUES OF TEACHING BY CLASSIFICATION REPAIRING AND RECOVERING PROCESS OF SKIN BY BIOPOLYMERS IN MEDICAL AND ENGINEERING EDUCATION
Amudeswari et al. Short‐term biocompatibility studies of hydrogel‐grafted collagen copolymers
RU2127095C1 (ru) Эндопротез молочной железы
JP2004503483A (ja) 低分子量ポリマー組成物
МЕДИЦИНСКОМ USING THE STATE-OF THE ART TECHNIQUES OF TEACHING BY CLASSIFICATION REPAIRING AND RECOVERING PROCESS OF SKIN BY BIOPOLYMERS IN MEDICAL AND ENGINEERING EDUCATION
Khule et al. AS A REVIEW ON HYDROGEL IN PHARMACEUTICAL SCIENCES
AU2006220922B2 (en) Polyacrylamide hydrogel and its use as an endoprosthesis
Valuev et al. Growing polymer hydrogels
Reid A histological evaluation of the biocompatibility of hydron implanted in Guinea pigs
US20050191271A1 (en) Process for preparing alcoholic polyamide interpolymers in the form of biocompatible hydrogels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/16 20060101AFI20030408BHEP

Ipc: A61L 27/54 20060101ALI20070308BHEP

Ipc: A61L 27/52 20060101ALI20070308BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070315

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60132025

Country of ref document: DE

Date of ref document: 20080131

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ROSENICH PAUL; GISLER CHRISTIAN PATENTBUERO PAUL R

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2298195

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071219

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080519

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BIOFORM INTERNATIONAL S.A.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080922

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: BIOFORM INTERNATIONAL S.A.

Effective date: 20081015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080929

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071219

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20180921

Year of fee payment: 18

Ref country code: DE

Payment date: 20180925

Year of fee payment: 18

Ref country code: FR

Payment date: 20180921

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20180920

Year of fee payment: 18

Ref country code: CH

Payment date: 20180924

Year of fee payment: 18

Ref country code: AT

Payment date: 20180918

Year of fee payment: 18

Ref country code: GB

Payment date: 20180924

Year of fee payment: 18

Ref country code: SE

Payment date: 20180924

Year of fee payment: 18

Ref country code: BE

Payment date: 20180920

Year of fee payment: 18

Ref country code: DK

Payment date: 20180924

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20181024

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60132025

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190929

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20191001

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200401

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191001

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190930

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 381356

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190928

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190928

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190929